Please login to the form below

Not currently logged in
Email:
Password:

EAMS

This page shows the latest EAMS news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland

Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland

Prior to this approval, Roche provided Alecensa via the UK-wide Early Access to Medicines Schemes (EAMS), which allows patients and doctors access to promising new unlicensed medicines that have a

Latest news

More from news
Approximately 11 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Can UK pharma rise to the post-Brexit challenge? Can UK pharma rise to the post-Brexit challenge?

    4.The Early Access to Medicine Scheme (EAMS) could be adopted more quickly by the NHS, to achieve patient access to new medicines more rapidly.

  • Lighting the way Lighting the way

    Ultimately the government says the Review's recommendatiosn have the potential to cut four years from the process, through a funded Early Access to Medicines Scheme (EAMS) alongside more speedy technology

  • Market access in Europe: balancing access and affordability Market access in Europe: balancing access and affordability

    in the Early Access to Medicines Scheme (EAMS), streamlining health technology assessment and facilitating commissioning and adoption.

  • Curbing the rise of drug resistance Curbing the rise of drug resistance

    The anti-microbial sector would also benefit greatly from enhanced patent protection and faster regulatory approval, via new regulatory programmes such as the UK's Early Access to Medicines Scheme (EAMS)

  • Creating a 21st century life sciences ecosystem Creating a 21st century life sciences ecosystem

    His plan to encourage this is the early access to medicines scheme (EAMS), a new policy set up (and led by Freeman) this year that is looking to speed up the ... He'd rather see all the key stakeholders work together and use the EAMS project, rather than

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics